Literature DB >> 24213855

Model system for irreversible inhibition of Nek2: thiol addition to ethynylpurines and related substituted heterocycles.

Honorine Lebraud1, Christopher R Coxon, Victoria S Archard, Carlo M Bawn, Benoit Carbain, Christopher J Matheson, David M Turner, Celine Cano, Roger J Griffin, Ian R Hardcastle, Ulrich Baisch, Ross W Harrington, Bernard T Golding.   

Abstract

Recent studies have shown that irreversible inhibition of Nek2 kinase [(Never in mitosis gene a)-related kinase 2], overexpression of which is observed in several cancers, can be achieved using Michael acceptors containing an ethynyl group, which target the enzyme's cysteine 22 residue lying near the catalytic site. The model studies described herein demonstrate an analogous capture of the ethynyl moiety in a series of ethynyl-heterocycles (e.g. 6-ethynyl-N-phenyl-9H-purin-2-amine) by N-acetylcysteine methyl ester in the presence of 1,4-diazabicyclo[2.2.2]octane in either dimethyl sulfoxide or N,N-dimethylformamide. Kinetic studies showed a 50-fold range in reactivity with 7-ethynyl-N-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine being the most reactive compound, whereas 4-ethynyl-N-phenyl-7H-pyrrolo[2,3-d]pyrimidin-2-amine was the least reactive. Studies of the isomeric compounds, 2-(3-((6-ethynyl-7-methyl-7H-purin-2-yl)amino)phenyl)acetamide and 2-(3-((6-ethynyl-9-methyl-9H-purin-2-yl)amino)phenyl)acetamide, revealed the N(7)-methyl isomer to be 5-fold more reactive than the 9-methyl isomer, which is ascribed to a buttressing effect in the N(7)-methyl compound. Comparison of the crystal structures of these isomers showed that the ethynyl group is significantly displaced away from the methyl group exclusively in the N(7)-methyl isomer with an sp(2) bond angle of 124°, whereas the corresponding angle in the N(9)-methyl isomer was the expected 120°. The results of this study indicate heterocyclic scaffolds that are likely to be more promising for inhibition of Nek2 and other kinases containing a reactive cysteine.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24213855     DOI: 10.1039/c3ob41806e

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  11 in total

Review 1.  Targeting NEK2 as a promising therapeutic approach for cancer treatment.

Authors:  Yanfen Fang; Xiongwen Zhang
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

2.  NEK2 promotes proliferation, migration and tumor growth of gastric cancer cells via regulating KDM5B/H3K4me3.

Authors:  Yiwei Li; Lijuan Chen; Lixing Feng; Mengli Zhu; Qiang Shen; Yanfen Fang; Xuan Liu; Xiongwen Zhang
Journal:  Am J Cancer Res       Date:  2019-11-01       Impact factor: 6.166

Review 3.  Role of NEK2A in human cancer and its therapeutic potentials.

Authors:  Jiliang Xia; Reinaldo Franqui Machin; Zhimin Gu; Fenghuang Zhan
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

4.  A new tool for the chemical genetic investigation of the Plasmodium falciparum Pfnek-2 NIMA-related kinase.

Authors:  Deborah F Mitcheson; Andrew R Bottrill; Katherine Carr; Christopher R Coxon; Celine Cano; Bernard T Golding; Roger J Griffin; Andrew M Fry; Christian Doerig; Richard Bayliss; Andrew B Tobin
Journal:  Malar J       Date:  2016-11-07       Impact factor: 2.979

5.  An Activity-Based Probe Targeting Non-Catalytic, Highly Conserved Amino Acid Residues within Bromodomains.

Authors:  Melissa D'Ascenzio; Kathryn M Pugh; Rebecca Konietzny; Georgina Berridge; Cynthia Tallant; Shaima Hashem; Octovia Monteiro; Jason R Thomas; Markus Schirle; Stefan Knapp; Brian Marsden; Oleg Fedorov; Chas Bountra; Benedikt M Kessler; Paul E Brennan
Journal:  Angew Chem Int Ed Engl       Date:  2018-12-27       Impact factor: 15.336

6.  Characterising covalent warhead reactivity.

Authors:  James S Martin; Claire J MacKenzie; Daniel Fletcher; Ian H Gilbert
Journal:  Bioorg Med Chem       Date:  2019-04-03       Impact factor: 3.641

7.  2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase.

Authors:  Christopher J Matheson; Christopher R Coxon; Richard Bayliss; Kathy Boxall; Benoit Carbain; Andrew M Fry; Ian R Hardcastle; Suzannah J Harnor; Corine Mas-Droux; David R Newell; Mark W Richards; Mangaleswaran Sivaprakasam; David Turner; Roger J Griffin; Bernard T Golding; Céline Cano
Journal:  RSC Med Chem       Date:  2020-05-22

8.  NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1.

Authors:  Xiaozhen Zhang; Xing Huang; Jian Xu; Enliang Li; Mengyi Lao; Tianyu Tang; Gang Zhang; Chengxiang Guo; Xiaoyu Zhang; Wen Chen; Dipesh Kumar Yadav; Xueli Bai; Tingbo Liang
Journal:  Nat Commun       Date:  2021-07-27       Impact factor: 14.919

Review 9.  Nek2 Kinase Signaling in Malaria, Bone, Immune and Kidney Disorders to Metastatic Cancers and Drug Resistance: Progress on Nek2 Inhibitor Development.

Authors:  Dibyendu Dana; Tuhin Das; Athena Choi; Ashif I Bhuiyan; Tirtha K Das; Tanaji T Talele; Sanjai K Pathak
Journal:  Molecules       Date:  2022-01-06       Impact factor: 4.927

10.  The Greatwall kinase safeguards the genome integrity by affecting the kinome activity in mitosis.

Authors:  Xavier Bisteau; Joann Lee; Vinayaka Srinivas; Joanna H S Lee; Joanna Niska-Blakie; Gifford Tan; Shannon Y X Yap; Kevin W Hom; Cheng Kit Wong; Jeongjun Chae; Loo Chien Wang; Jinho Kim; Giulia Rancati; Radoslaw M Sobota; Chris S H Tan; Philipp Kaldis
Journal:  Oncogene       Date:  2020-09-25       Impact factor: 8.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.